Lexicon Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: The Woodlands TX United States (1995)

Organization Overview

First Clinical Trial
2008
NCT00691808
First Marketed Drug
2007
telotristat ethyl (xermelo)
First NDA Approval
2017
telotristat ethyl (xermelo)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Lexicon Pharmaceuticals | Lexicon Pharmaceuticals, Inc | Lexicon Pharmaceuticals, Inc. | LEXICON PHARMS INC

Indications

Approved Indications


 

Diarrhea

Malignant Carcinoid Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Carcinoid Tumor (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Diarrhea (Phase 2)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Liver Diseases (Phase 1)

Malignant Carcinoid Syndrome (Phase 3)

Memory Disorders (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Ocular Hypertension (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Renal Insufficiency (Phase 1)

Serotonin Syndrome (Phase 3)

Syndrome (Phase 3)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 50
  • # of Trial APIs: 24